Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24652926 | 0.94 | ALDH1A1 (0.45) | ALDH1A1USP2GAANPC1CYP3A4 | |
| SCHEMBL20791549 | 0.94 | ALDH1A1 (0.46) | ALDH1A1USP2GAAUBE2NKMT2A | |
| SCHEMBL24652976 | 0.88 | GAA (0.46) | ALDH1A1USP2GAACYP3A4CYP2C9 | |
| SCHEMBL20811643 | 0.88 | ALDH1A1 (0.46) | ALDH1A1USP2GAACYP3A4CYP2C9 | |
| SCHEMBL29585938 | 0.88 | ALDH1A1 (0.46) | ALDH1A1USP2GAACYP3A4CYP2C9 | |
| SCHEMBL20790599 | 0.88 | ALDH1A1 (0.45) | ALDH1A1USP2GAACYP3A4CYP2C9 | |
| SCHEMBL30524886 | 0.88 | ALDH1A1 (0.45) | ALDH1A1USP2GAACYP3A4CYP2C9 | |
| SCHEMBL24653125 | 0.87 | ALDH1A1 (0.49) | ALDH1A1USP2GAANPC1CYP3A4 | |
| SCHEMBL20791004 | 0.87 | ALDH1A1 (0.44) | ALDH1A1USP2GAAUBE2NKMT2A | |
| SCHEMBL24262127 | 0.87 | ALDH1A1 (0.44) | ALDH1A1USP2GAAUBE2NKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885USP2 3131/4885GAA 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.